aneurysmal subarachnoid hemorrhage epidemiology forecast
DelveInsight’s ‘Aneurysmal Subarachnoid Hemorrhage (aSAH) —Epidemiology Forecast–2034’ report delivers an in-depth understanding of the disease, historical and forecasted Aneurysmal Subarachnoid Hemorrhage (aSAH) epidemiology in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
Geographies Covered
• The United States
• EU5 (Germany, France, Italy, Spain, and the United Kingdom)
• Japan
Study Period: 2017–2034
Aneurysmal Subarachnoid Hemorrhage (aSAH) Understanding
Spontaneous (nontraumatic) subarachnoid hemorrhage (SAH) usually results from the rupture of a cerebral aneurysm. These aneurysms, which are located at the branching point of proximal intracranial arteries, are not uncommon and found in about 2% of the adult population (and even more frequently in those with a family history of a ruptured aneurysm or polycystic kidney disease). Aneurysmal SAH is a worldwide health burden with high fatality and permanent disability rates. It is defined, according to the standard criteria, as an abrupt onset of a severe headache and/or loss of consciousness, with or without focal neurological signs, with CT, necropsy, or lumbar puncture, evidence of focal or generalized blood in the subarachnoid space.
An aneurysm is often an incidental finding during investigations for other causes of intracranial pathology. Most aneurysms remain undetected during one's lifetime or until rupture. Aneurysms may present in several ways, such as headache, bilateral temporal hemianopsia, bilateral lower extremity weakness (anterior communicating artery aneurysm), facial or orbital pain, epistaxis, symptoms of brainstem dysfunction (posterior circulation aneurysms) and others.
Aneurysmal Subarachnoid Hemorrhage (aSAH) Epidemiology Perspective by DelveInsight
The disease epidemiology covered in the report provides historical as well as forecasted epidemiology segmented by Incident Cases of Aneurysmal Subarachnoid Hemorrhage (aSAH), Incidence of Aneurysmal Subarachnoid Hemorrhage (aSAH), Age-specific Incidence of Aneurysmal Subarachnoid Hemorrhage (aSAH), WFNS Grade wise segmentation of Aneurysmal Subarachnoid Hemorrhage (aSAH), Fisher Grade wise segmentation of Aneurysmal Subarachnoid Hemorrhage (aSAH), and Clinical Manifestations of Aneurysmal Subarachnoid Hemorrhage (aSAH) scenario of Aneurysmal Subarachnoid Hemorrhage (aSAH) in the 7MM covering the United States, EU5 countries (Germany, France, Italy, Spain, and United Kingdom) and Japan from 2017 to 2034. The additional segments include Gender-specific Incidence of Aneurysmal Subarachnoid Hemorrhage (aSAH) and Hunt–Hess Grade wise segmentation of Aneurysmal Subarachnoid Hemorrhage (aSAH).
Aneurysmal Subarachnoid Hemorrhage (aSAH) Detailed Epidemiology Segmentation
• In the 7MM, the total incident of Subarachnoid Hemorrhage (SAH) was estimated to be 63,072 cases in 2017 whereas the total incident of Aneurysmal Subarachnoid Hemorrhage (aSAH) was estimated to be 53,611.
• According to the analysis, the estimated cases in WFNS grade-wise segmentation in 2017 for I-II, III, IV-V was 1,740, 305, and 1,196 respectively. The anticipated decrease in the grade wise segmentation in the forecast period is 1,393, 244 and 957 in Germany.
• Several manifestations act as a contributor in course of development of aSAH. A total of 9,193, 3,940, 9,718, 10,112, 6,960 and 4,597 cases develop during aSAH i.e., Angiographic Vasospasm, Delayed ischemic neurologic deficit (DIND), Headache, Nausea or Vomiting, Loss of Conciousness and Nuchal Rigidity in 2017, which as per Delveinsight assessments will decrease to 8,391, 3,596, 8,870, 9,230, 6,353 and 4,195 cases, respectively, in 2034 in the US.
• According to the analysis, the estimated cases in Fisher grade-wise segmentation in 2017 for I-II, III-IV is 468, and 1,930 respectively. The anticipated decrease in the grade wise segmentation in the forecast period is 374 and 1,545 (France).
• The total incidence of Subarachnoid Hemorrhage (SAH) in the 7MM is expected to increase at a CAGR of 0.41% for the study period of 2017–2034.
Scope of the Report
• The report covers the descriptive overview of Aneurysmal Subarachnoid Hemorrhage (aSAH), explaining its causes, signs and symptoms, pathophysiology and currently available therapies.
• The report provides insight into the 7MM historical and forecasted patient pool covering the United States, EU5 countries (Germany, France, Italy, Spain, and United Kingdom) and Japan.
• The report assesses the disease risk and burden and highlights the unmet needs of Aneurysmal Subarachnoid Hemorrhage (aSAH).
• The report provides the segmentation of the disease epidemiology for 7MM by Total Prevalent Cases of Aneurysmal Subarachnoid Hemorrhage (aSAH), Total Diagnosed and Treated Cases of Aneurysmal Subarachnoid Hemorrhage (aSAH).
Report Highlights
• Eleven-Year Forecast of Aneurysmal Subarachnoid Hemorrhage (aSAH)
• 7MM Coverage
• Incident Cases of Aneurysmal Subarachnoid Hemorrhage (aSAH)
• Incidence of Aneurysmal Subarachnoid Hemorrhage (aSAH)
• Age-specific Incidence of Aneurysmal Subarachnoid Hemorrhage (aSAH)
• WFNS Grade wise segmentation of Aneurysmal Subarachnoid Hemorrhage (aSAH)
• Fisher Grade wise segmentation of Aneurysmal Subarachnoid Hemorrhage (aSAH)
• Clinical Manifestations of Aneurysmal Subarachnoid Hemorrhage (aSAH)
Key Questions Answered
• What is the disease risk, burden and unmet needs of Aneurysmal Subarachnoid Hemorrhage (aSAH)?
• What is the historical Aneurysmal Subarachnoid Hemorrhage (aSAH) patient pool in the United States, EU5 (Germany, France, Italy, Spain, and the UK) and Japan?
• What would be the forecasted patient pool of Aneurysmal Subarachnoid Hemorrhage (aSAH) at the 7MM level?
• What will be the growth opportunities across the 7MM with respect to the patient population pertaining to Aneurysmal Subarachnoid Hemorrhage (aSAH)?
• Out of the above-mentioned countries, which country would have the highest incident population of Aneurysmal Subarachnoid Hemorrhage (aSAH) during the forecast period (2020–2034)?
• At what CAGR the population is expected to grow across the 7MM during the forecast period (2020–2034)?
Reasons to buy
The Aneurysmal Subarachnoid Hemorrhage (aSAH) report will allow the user to -
• Develop business strategies by understanding the trends shaping and driving the 7MM Aneurysmal Subarachnoid Hemorrhage (aSAH) market.
• Quantify patient populations in the 7MM Aneurysmal Subarachnoid Hemorrhage (aSAH).
• The Aneurysmal Subarachnoid Hemorrhage (aSAH) epidemiology report and model were written and developed by Masters and Ph.D. level epidemiologists.
• The Aneurysmal Subarachnoid Hemorrhage (aSAH) epidemiology model developed by DelveInsight is easy to navigate, interactive with dashboards, and epidemiology based on transparent and consistent methodologies. Moreover, the model supports data presented in the report and showcases disease trends over the eleven-year forecast period using reputable sources.
Key Assessments
• Patient Segmentation
• Disease Risk and Burden
• Risk of disease by the segmentation
• Factors driving growth in a specific patient population
